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Background: Advances in genomics technology have led to a dramatic increase in the number of published genetic
association studies. Systematic reviews and meta-analyses are a common method of synthesizing findings and providing
reliable estimates of the effect of a genetic variant on a trait of interest. However, summary estimates are subject to bias
due to the varying methodological quality of individual studies. We embarked on an effort to develop and evaluate a tool
that assesses the quality of published genetic association studies. Performance characteristics (i.e. validity, reliability, and
item discrimination) were evaluated using a sample of thirty studies randomly selected from a previously conducted
systematic review.
Results: The tool demonstrates excellent psychometric properties and generates a quality score for each study with
corresponding ratings of ‘low’, ‘moderate’, or ‘high’ quality. We applied our tool to a published systematic review to
exclude studies of low quality, and found a decrease in heterogeneity and an increase in precision of summary estimates.
Conclusion: This tool can be used in systematic reviews to inform the selection of studies for inclusion, to conduct
sensitivity analyses, and to perform meta-regressions.
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Completion of the human genome project along with
rapid advances in genotyping technology has resulted in
an increase in the number of published genetic associ-
ation studies (Additional file 1: Figure S1) [1].
Systematic reviews and meta-analyses are a common
approach to synthesizing these data. However, in com-
bining studies, authors must consider potential limita-
tions and biases introduced by included studies. In
addition to the challenges common to classical epi-
demiological designs (i.e. sampling error, confounding,
and selective reporting), genetic association studies face
additional unique threats to validity (Table 1). Notably,
because a vast majority of genotype-phenotype associa-
tions have modest effect sizes, genetic studies must be* Correspondence: anands@mcmaster.ca
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unless otherwise stated.appropriately powered, often having sample sizes of
thousands of subjects. Additional threats to validity in-
clude i) quality of genotyping, ii) batch related differ-
ences in genotyping, which can manifest as false
associations if all cases are in one batch and controls are
in the other, iii) choice of inheritance model, and iv)
genotype-phenotype relationships confounded by gene-
gene and gene-environment interactions [1–3]. Ultim-
ately, inferences from genetic association studies require
careful assessment of traditional epidemiologic biases as
well as genetic specific threats to validity.
Several guidelines have been published to guide the con-
duct and reporting of genetic association studies [3–8].
Among the most notable are the Strengthening the
Reporting of Genetic Association Studies (STREGA) and
Strengthening the Reporting of Genetic Risk Prediction
Studies (GRIPS) statements. Furthermore, the Human
Genome Epidemiology Network (HuGENet) Working
Group developed a grading scheme to aid researchers inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Common bias in genetic association studies
Bias Impact on results of genetic association study
Phenotype definition Unclear definition of phenotype or use of non-standardized definitions can lead to noise in the outcome, which
compromises ability to identify corresponding susceptibility variants.
Genotyping
misclassification
Differential misclassification of genotypes can positively or negatively affect associations depending on the direction of
misclassification. Non-differential misclassification of genotypes will bias association toward the null.
Selection of sample Source of cases and controls or participants for analysis of quantitative traits can bias the association; for example,
contrasting hospital cases with controls from the general population will inflate the association.
Confounding by ethnic
origin
If populations from ethnic groups differ in frequency of risk alleles, confounding may occur if the populations are unevenly
distributed across comparison groups.
Multiple testing Testing a multitude of genetic variants against a phenotype creates a possibility of finding significant associations by
chance (type 1 error).
Relatedness Consanguinity in genetic association studies can distort the genotype-phenotype associations. Even in supposed unrelated
populations, some individuals may be related. Relatedness should therefore be investigated with additional methods and
adjusted for in the statistical analysis.
Treatment effects The phenotype under investigation may be modified by treatments and hence distort the size of association between
genetic variants and the phenotype of interest.
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dence based on three criteria: i) amount of evidence, ii)
replication, and iii) protection from bias [2]. Each study is
marked as ‘A’, ‘B’, or ‘C’ based on the strength of evidence
on the three criteria and a cumulative rating is then ob-
tained using different combinations. While the scheme
provides a good baseline to assess evidence in genetic as-
sociation studies, it is not intuitive to use, and relies on a
checklist approach, which has been shown in literature to
be less reliable than global rating scales [9]. Moreover, to
our knowledge, the grading scheme itself has not been for-
mally tested for validity and reliability.
In this paper, we: i) describe the development of a tool
to assess global quality of published genetic association
studies, ii) evaluate the tool’s reliability and validity, and
iii) investigate whether the reliability and validity of the
tool differs based on user’s familiarity with genetic asso-
ciation studies, since there is some evidence to suggest
that experts outperform novices on evaluations involving
knowledge across different content areas [10–13].
Methods
Development of the Q-Genie tool
Published guidelines and recommendations on appropri-
ate conduct of genetic association studies, including the
STREGA and GRIPS guidelines as well as recommenda-
tions by Human Molecular Genetics, Diabetologia, Nature
Genetics, and individual research groups [3, 5, 7, 8, 14],
were used to create a list of items with potential impact on
quality. The items were divided into nine categories: ration-
ale for study, selection of sample, classification of exposure,
classification of outcome, sources of bias, presentation of
statistical plan, quality of statistical methods, testing of as-
sumptions made in genetic studies, and interpretation of re-
sults. The categories were then formulated into questions
and a description was included to provide context for eachquestion. A Likert type rating scale was created with seven
categories anchored by ‘poor’ and ‘excellent’ to ensure mini-
mum loss of precision and reliability and to account for
end aversion bias [15]. Additionally, the positive side of the
scale was expanded to account for positive skew bias (a
tendency to select responses on the favorable end of the
scale leading to a ceiling effect in positive ratings) [15]. The
final scale used in our tool is depicted in Fig. 1.
A preliminary draft of the tool was sent to five experts
with experience in conducting genetic association studies
and knowledge in developing measurement tools. The ex-
perts were asked to provide suggestions for improvement
and comment on the clarity of the items. Discussion with
the experts prompted addition of the following aspects
lacking from the preliminary draft of the tool: i) checking
for samples with outlying heterozygosity, ii) checking both
sample and genetic variant missingness, iii) randomization
of samples at genotyping stage, iv) checking for concord-
ance of reported sex with genetically determined sex, v)
concordance of reported ethnicity with genetically deter-
mined ethnicity, and vi) sample size/power considerations.
Additionally, the question on classification of the genetic
variant was split into two questions, technical and non-
technical classification, respectively.Psychometric assessment
We tested the validity and reliability of the Q-Genie tool
using a sample of thirty studies randomly selected from a
previously conducted systematic review on the association
of single nucleotide polymorphisms with type 2 diabetes
mellitus in South Asians [16]. Characteristics of the in-
cluded studies are presented in Additional file 1: Table S1.
We used this published systematic review as our sampling
frame, instead of a random selection of published studies
from scientific databases (e.g. MEDLINE), to ensure
Fig. 1 Likert scale used in the Q-Genie tool
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tematic reviews.
Four raters, 2 ‘users’ and 2 ‘non-users’, were recruited from
the Departments of Clinical Epidemiology & Biostatistics
and Medicine at McMaster University. Raters were strati-
fied by user-status, defined as having familiarity with gen-
etic association studies, i.e. if the rater routinely reads/
conducts genetic association studies. All four raters each
rated the thirty studies for every item of the Q-Genie.
Item discrimination The extent to which each item dis-
tinguishes ‘good’ from ‘bad’ quality studies was assessed
using item-total correlations. Items with item-total cor-
relations below 0.2 or above 0.9 were considered unin-
formative and were candidates for exclusion from the
tool [15].
Reliability Generalizability theory (G-theory) was used to
establish inter-rater reliability (the extent to which a rating
from one rater can be generalized to another), internal
consistency (the extent to which a rating on one question
can be generalized to another), inter-use reliability (the ex-
tent to which a rating from users can be generalized to
non-users), and overall reliability. Formulas for the coeffi-
cients are presented in Additional file 1. All four raters,
users and non-users, rated each study. Data from the rat-
ings were used to ascertain G-coefficients, calculated sep-
arately for users and non-users, with the exception of
inter-user reliability, for which data from both groups
were used Raters used in this study were considered a ran-
dom sample of all possible raters, and therefore we report
absolute error G-coefficients.
Construct validity We tested the construct that high
quality studies are cited more often and published in
higher impact journals. These constructs were evaluated
by testing their correlation with total score acquired on
Q-Genie. We expected those studies acquiring higher
scores on the Q-Genie tool to be published in journals
with higher impact factors and cited more often than
studies with lower scores on our tool. To account for
the fact that some studies were published only in the
preceding year and may not have had enough time to be
cited, we assessed average citations per year as well as totalcitations. Additionally, we accounted for self-citation by ex-
cluding citations of the paper made by the first and senior
authors, as this may artificially inflate the count and bias
our assessment of validity. Citation count was ascertained
using Web of Science (all databases). Correlation was deter-
mined using Spearman’s ρ.Creating cut-points for low, moderate, and high quality
on the Q-Genie tool
In addition to the questions on Q-Genie, raters were
given a question on global impression – “rate overall
quality of the study”. Ratings of 1 and 2 on this global
impression question were classified as ‘low’, 3 and 4 as
‘moderate’, and 5–7 as ‘high’ . Borderline groups regres-
sion [17], a technique used to establish cut-points, was
performed with total score on Q-Genie as the outcome
and classification as ‘low’, ‘moderate’, or ‘high’ on the
global impression question as the predictor. In this man-
ner, total scores on Q-Genie corresponding to ‘low’,
‘moderate’, and ‘high’ on the global impression question
were determined. The global impression question was
only used to establish cut-points and is not part of Q-
Genie.Empirical evaluation of the Q-Genie tool
In addition to the psychometric assessment, we per-
formed an empirical evaluation of the tool using pub-
lished data from a meta-analysis investigating the
association of CDKAL1 rs7754840 with type 2 diabetes
[16]. Meta-analysis of this SNP contained significant het-
erogeneity and included seven datasets from six studies,
making it conducive to this exercise. Characteristics of
these studies are presented in Additional file 1: Table S2.
We rated all six studies included in the meta-analysis of
CDKAL1 rs7754840 using the Q-Genie tool. If the tool
performed as anticipated, the effect estimate for this
SNP should be more precise and less heterogeneous
after exclusion of low quality studies, determined by Q-
Genie, compared to the summary estimate ascertained
using all studies. The I2 statistic and Chi square test
were used to establish heterogeneity.
Reliability analyses were conducted using G String IV
(version 6.1.1). All other analyses were conducted on R
(version 3.0.2) and SPSS (version 20.0.0).
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Description of the final tool
The final version of the Q-Genie tool contained 11 items
(i.e. questions) marked on a 7-point Likert scale covering
the following themes: scientific basis for development of
the research question, ascertainment of comparison groups
(i.e. cases and controls), technical and non-technical classi-
fication of genetic variant tested, classification of the out-
come, discussion of sources of bias, appropriateness of
sample size, description of planned statistical analyses, stat-
istical methods used, test of assumptions in the genetic
studies (e.g. agreement with the Hardy Weinberg equilib-
rium), and appropriate interpretation of results. The tool
took approximately 20 min to complete per study.
Psychometric assessment
Item discrimination Item-total correlations (ITC) were
calculated to determine the discrimination of each item
(Tables 2 and 3 for users and non-users, respectively).
As previously described, an ITC below 0.2 or above 0.9
are generally understood to be uninformative and the
corresponding items are considered for exclusion [15].
Overall, no item had an ITC below 0.2 or above 0.9 for
either group. The item with the lowest ITC (0.38) for
users was question 2, which asked to “rate the study on
the classification of the outcome (e.g. disease status or
quantitative trait)”. In contrast, question 1 had the low-
est ITC for non-users (0.43).
A distribution of average ratings by group for each item is
presented in Fig. 2. From the 11 items, item 1, which
asked the rater to rate the study on the adequacy of the
presented hypothesis and rationale, had the highest en-
dorsement, understood as a rating of 6 or 7 on the 7-point
scale, for both groups. On average, users endorsed this
item 78 % of the time and non-users endorsed it 60 % of
the time. Normally, high endorsement of a question mayTable 2 Item-total correlations and Cronbach’s α if deleted for users
Item Question
Question 1 Please rate the study on the adequacy of the presented hypot
Question 2 Please rate the study on the classification of the outcome (e.g.
Question 3 Please rate the study on the description of comparison groups
Question 4 Please rate the study on the technical classification of the expo
Question 5 Please rate the study on the non-technical classification of the
Question 6 Please rate the study on the disclosure and discussion of sourc
Question 7 Please rate whether the study was adequately powered.
Question 8 Please rate the study on description of planned analyses.
Question 9 Please rate the study on the statistical methods.
Question 10 Please rate the study on the description and test of all assump
Question 11 Please rate the study on whether conclusions drawn by the au
and appropriate methods.suggest that the question is not providing discriminative
information about each study, since all studies tend to per-
form well on the item. We did not, however, exclude item
1 from our tool as it provides evidence of face validity and
had an acceptable ITC in both groups.
Reliability Analysis of reliability was conducted using G-
theory. Inter-rater reliability, internal consistency, and
overall reliability were assessed for users and non-users.
Inter-rater reliability was 0.74 and 0.45 for users and non-
users, respectively. Internal consistency was similar in
both groups (G-coefficient of 0.82 in users and 0.80 in
non-users). Agreement between users and non-users was
0.64. Lastly, overall reliability, across raters and items, was
0.64 for users and 0.42 for non-users (Table 4).
Validity Spearman’s ρ for correlation between impact
factor, average citations per year, and total citations, with
total score on the Q-Genie tool are presented in Table 5.
User scores had a stronger correlation with impact fac-
tor and average citations per year than non-user scores,
although all values were above ρ = 0.30. Total citations
to date had the weakest correlation with scores on Q-
Genie for both users and non-users (Spearman’s ρ = 0.40
and 0.33 for users and non-users, respectively), likely be-
cause total citations are confounded by time since publi-
cation. Spearman’s ρ did not change for either users or
non-users when self-citations were excluded from the
citation counts.
Classification as low, moderate, or high quality from total
score
Borderline groups regression analysis indicated use of
the following cut-points to designate low, moderate, and
high quality studies for studies with case/control status




hesis and rationale. 0.53 0.94
disease status or quantitative trait). 0.38 0.94
(e.g. cases and controls). 0.51 0.94
sure (i.e. the genetic variant). 0.86 0.92
exposure (i.e. the genetic variant). 0.55 0.94




tions and inferences. 0.80 0.93
thors were supported by the results 0.88 0.92





Question 1 Please rate the study on the adequacy of the presented hypothesis and rationale. 0.43 0.90
Question 2 Please rate the study on the classification of the outcome (e.g. disease status or quantitative trait). 0.53 0.89
Question 3 Please rate the study on the description of comparison groups (e.g. cases and controls). 0.51 0.89
Question 4 Please rate the study on the technical classification of the exposure (i.e. the genetic variant). 0.72 0.88
Question 5 Please rate the study on the non-technical classification of the exposure (i.e. the genetic variant). 0.56 0.89
Question 6 Please rate the study on the disclosure and discussion of sources of bias. 0.63 0.89
Question 7 Please rate whether the study was adequately powered. 0.76 0.88
Question 8 Please rate the study on description of planned analyses. 0.55 0.89
Question 9 Please rate the study on the statistical methods. 0.58 0.89
Question 10 Please rate the study on the description and test of all assumptions and inferences. 0.43 0.90
Question 11 Please rate the study on whether conclusions drawn by the authors were supported by the results
and appropriate methods.
0.84 0.88
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cate studies of moderate quality, and >45 indicate
good quality studies (Fig. 3). Similarly, cut-points for
studies without control groups (e.g. studies of quanti-
tative traits) were created by excluding question 3
from the calculation of the total score on Q-Genie,
since this question asked raters to assess the control
group: scores ≤32 on the Q-Genie tool indicate poor
quality studies, >32 and ≤40 indicate studies of mod-
erate quality, and >40 indicate good quality studies.
Applying these criteria to our sample of 30 studies re-
vealed that 8 out of 30 studies were of poor quality (27 %),
17 were of moderate quality (56 %), and 5 were of high
quality (17 %). Of the poor quality studies, a majority had
biased technical and non-technical classification of the
genetic variant (50 % had a score <3 and 100 % had a
score <3 on the respective question), inadequateFig. 2 Endorsement of items on the Q-Genie tool in users and non-usersdisclosure of potential sources of bias (100 % had a score
<3), inappropriate power (88 % had a score <3), poor stat-
istical methods (75 % had a score <3), and inadequate test-
ing of inferences (63 % had a score <3).
Empirical evaluation
We applied the Q-Genie to an existing published meta-
analysis of CDKAL1 rs7754840 [16]. After excluding
studies with a score of ≤35 on the Q-Genie tool, (those
studies deemed to be of poor quality), the heterogeneity
in meta-analysis was reduced from an I2 of 72 % (95 %
CI 38 %–87 %), Q-statistic of 21.1 (6 d.f.; p < 0.01) to an
I2 of 0 % (95 % CI 0 %–75 %), Q-statistic of 3.04 (5 d.f.;
p = 0.69) (Fig. 4). The summary effect size changed from
1.25 (95 % CI 1.09–1.45) to 1.15 (95 % CI 1.07–1.24). Al-
though the difference between the two effect sizes is not
statistically significant, the meta-analysis estimate after
Table 4 G-coefficients of reliabilities, stratified by
user-status
Reliability Users
(nstudies = 30; nraters = 2)
Non-users
(nstudies = 30; nraters = 2)




*all four raters were used to estimate this coefficient.
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intervals and is more precise.
Discussion
We have developed and validated a tool that assesses the
global quality of published genetic association studies. The
Q-Genie can be used to assess quality of genetic associ-
ation studies in systematic reviews and meta-analyses,
which can inform selection of studies for inclusion, exam-
ine the sensitivity of pooled effect sizes to indicators of
study quality, and/or explain heterogeneity. The tool dem-
onstrated good performance characteristics in a small
sample of studies. Additionally, we applied our tool to a
published systematic review of studies and found a de-
crease in heterogeneity and an increase in precision of es-
timates when used to exclude low quality studies.
Validity and Reliability We assessed the validity of the
Q-Genie tool by measuring the correlation between pre-
defined constructs, specifically impact factor, citations per
year, and total citations with the total Q-Genie score, using
Spearman’s ρ. Our findings suggest that Q-Genie demon-
strates construct validity in both groups, using measures
of impact as a criterion. Other forms of validity should be
tested in the future, including predictive, concurrent, as
well as convergent and discriminative validity.
We used G-coefficients to estimate the reliability of
the Q-Genie tool, which have previously been used to
test other instruments in the psychometric literatureTable 5 Spearman’s ρ correlations of total scores on
Q-Genie with impact factor and citation count, stratified by
user-status
Construct Users
(nstudies = 30; nraters = 2)
Non-users
(nstudies = 30; nraters = 2)
Impact factor 0.61 (p < 0.01) 0.45 (p = 0.02)
Average citations per
year




0.52 (p < 0.01) 0.39 (p = 0.03)
Total citations to date 0.40 (p = 0.03) 0.33 (p = 0.08)[18]. Our results show that Q-Genie is highly reliable in
users (defined as those who read/conduct genetic associ-
ation studies frequently) and moderately so in non-
users, which is not surprising since users presumably
have a better understanding of quality in genetic associ-
ation studies and are likely to agree more with each
other than non-users. Additionally, data from studies in
behavioral psychology suggest that people rate individual
components based on intuitive impressions from global
observations, and thus it appears logical that while
different, both user and non-user estimates are reliable
[19, 20]. We expect that most users of Q-Genie will be
experts in practice.
Empirical evaluation When the tool was applied to
studies included in a meta-analysis of a well-known SNP
associated with type 2 diabetes, we found that by exclud-
ing studies graded as poor quality by Q-Genie, we were
able to substantially reduce heterogeneity and increase
precision of the summary estimate. This furthers our con-
fidence in the utility of the tool for use with systematic
reviews and meta-analyses. Use of the tool may also en-
courage authors to explore other sources of heterogeneity,
such as genetic heterogeneity, gene-environment interac-
tions, and gene-gene interactions, if the possibility of
between-study heterogeneity due to low-quality data is
eliminated.
Limitations There are some limitations to our tool.
Firstly, data from the four reviewers suggests that the
tool takes approximately 20 min per study to complete,
slightly longer for non-users (mean of 21 min, 15 s) than
users (mean of 18 min, 45 s). Therefore, rating the qual-
ity of 30 studies included in a systematic review using
Q-Genie would take about 10 h. However, this estimate
is comparable with time-to-complete measures of other
tools in the literature, such as the Newcastle-Ottawa
Scale and AMSTAR [21–23]. Additionally, once accus-
tomed to the tool, raters likely become faster. Though
the procedure may be time intensive, the gains in scientific
rigor appear well worth the effort as demonstrated by ap-
plication to the systematic review of the CDKAL1 SNP.
Secondly, as with other global scoring tools, it is possible
for a study to receive low scores on 2 dimensions, yet high
scores on all others, and thus be considered a globally
‘high quality’ study. This can have limitations for answer-
ing specific research questions. However, because it is pos-
sible to obtain a score on each section using Q-Genie,
users can be mindful of performance on each dimension.
Lastly, because this is a pilot assessment with 30 studies
and 4 reviewers, additional testing is warranted to gain
support for our findings.
Q-Genie is available for download from <http://
fhs.mcmaster.ca/pgp/links.html>. We note that our tool
Fig. 3 Plot of borderline groups regression depicting total scores on the Q-Genie tool corresponding with ‘low’ , ‘moderate’ , and ‘high’ quality of
genetic association study
Sohani et al. BMC Genetics  (2015) 16:50 Page 7 of 8would benefit from testing in a larger sample of studies
as well as an assessment of additional measures of valid-
ity, and we encourage other groups to further test our
tool. We also welcome comments that can be used to in-
form revisions of the tool.Fig. 4 Forest plot of CDKAL1 rs7754840 with and without exclusion of lowConclusions
Based on our evaluation of 30 studies from a published
systematic review, it appears that many publications in
literature may be of poor quality despite published
guidelines designed to improve the quality of geneticquality studies
Sohani et al. BMC Genetics  (2015) 16:50 Page 8 of 8association studies. The Q-Genie tool was developed
and validated to facilitate the assessment of published
studies and to ultimately identify high quality studies
when planning meta-analyses of genetic association
studies. Integration of our tool into systematic reviews
and meta-analyses can help improve the state of evi-
dence in the field of genetic epidemiology, which is cur-
rently plagued with irreproducible findings. Our data
shows that Q-Genie demonstrates good inter-rater reli-
ability, internal consistency, and overall reliability. We
encourage using the Q-Genie tool as it can substantially
increase the quality of meta-analyses in genetic associ-
ation studies.Additional file
Additional file 1: Supplementary Box 1 Formulas for absolute error
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